Press "Enter" to skip to content

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma – PRNewswire

admin 0

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma  PRNewswire

SOUTH SAN FRANCISCO, Calif., June 19, 2019 /PRNewswire/ — Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the …

“lymphoma cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *